XML 15 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Total Athenex, Inc. Stockholders' Equity
Non-Controlling Interests
Beginning balance at Dec. 31, 2015 $ 98,044 $ 40 $ 206,679 $ (107,391) $ (223) $ (1,545) $ 97,560 $ 484
Beginning balance, shares at Dec. 31, 2015   40,330,124       (422,328)    
Issuance/sale of common stock 8,500 $ 1 8,499       8,500  
Issuance/sale of common stock, shares   1,133,332            
Issuance of common stock in connection with satisfaction of contingent consideration 2,843 $ 1 2,842       2,843  
Issuance of common stock in connection with satisfaction of contingent consideration, shares   315,810            
Stock-based compensation cost 3,877   3,877       3,877  
Restricted stock expense 2,166   2,166       2,166  
Repurchase of common stock, at cost (2,216)         $ (2,216) (2,216)  
Repurchase of common stock, shares           (246,200)    
Stock options exercised 14   14       14  
Stock options exercised, shares   5,440            
Non-controlling interests 519             519
Net loss (23,149)     (23,039)     (23,039) (110)
Other comprehensive income (loss), net of tax (364)       (364)   (364)  
Ending balance at Jun. 30, 2016 90,234 $ 42 224,077 (130,430) (587) $ (3,761) 89,341 893
Ending balance, shares at Jun. 30, 2016   41,784,706       (668,528)    
Beginning balance at Dec. 31, 2016 34,669 $ 42 237,581 (195,106) (1,304) $ (7,406) 33,807 862
Beginning balance, shares at Dec. 31, 2016   42,342,706       (1,656,920)    
Issuance/sale of common stock 64,194 $ 7 64,187       64,194  
Issuance/sale of common stock, shares   6,900,000            
Conversion of bonds 85,000 $ 8 84,992       85,000  
Conversion of bonds, shares   7,727,273            
Stock-based compensation cost 7,740   7,740       7,740  
Stock-based compensation cost, shares   400,000            
Research and development licensing fee satisfied with stock 6,250 $ 1 6,249       6,250  
Research and development licensing fee satisfied with stock, shares   568,182            
Vesting of restricted stock 1,080 $ 1 1,079       1,080  
Vesting of restricted stock, shares   391,982            
Stock options and warrants exercised $ 439   439       439  
Stock options and warrants exercised, shares   406,386            
Repurchase of common stock, shares (16,000)         (16,000)    
Stock options exercised, shares 72,320              
Non-controlling interests $ 49             49
Net loss (79,693)     (79,613)     (79,613) (80)
Other comprehensive income (loss), net of tax 646       646   646  
Ending balance at Jun. 30, 2017 $ 120,374 $ 59 $ 402,267 $ (274,719) $ (658) $ (7,406) $ 119,543 $ 831
Ending balance, shares at Jun. 30, 2017   58,736,529       (1,672,920)